MRNA vs BIIB
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Aug 03, 2026
MRNA
BIIB
Investment Advisor Scores
BIIB
AI Analyst Insights
Detailed Metrics Comparison
| Metric | MRNA | BIIB | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 23.0415 | 17.2117 | BIIB |
| PEG Ratio | 0 | 5.0607 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 260.2% | 3.4% | MRNA |
| Earnings Growth | -85.1% | -84.8% | BIIB |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 51.3/100 | 55.4/100 | BIIB |
| Profit Margin | -143.6% | 8.3% | BIIB |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | HOLD | Tie |
Relative Price Performance (Last 90 Days)
Current Technical Phase
MRNA
NeutralMixed signals - no dominant trend phase, RSI 41
BIIB
MarkupPrice above SMA50, rising 50-day trend (2.4% over 20 days), RSI 50
Fundamentals Snapshot
| Metric | MRNA | BIIB |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -11.5 | 12.2 |
| Trailing P/E | — | 36.9 |
| Revenue (TTM) | — | — |
| Revenue Growth | 2.6% | 0.0% |
| Gross Margin | -0.7% | 0.8% |
| Operating Margin | -1.3% | 0.2% |
| EPS | -8.14 | 5.63 |
| Dividend Yield | — | — |